Valbenazine approved by U.S. FDA for treatment of chorea in HD
Neurocrine Biosciences, Inc. announced the U.S. Food and Drug Administration (FDA) has approved INGREZZA ® (Valbenazine) capsules for treatment of
Read more
Update from Prilenia Regarding PROOF-HD Clinical Trials
Dear Huntington disease (HD) community, We have received an update on PROOF-HD, the phase 3, randomized, double-blind, placebo-controlled study to
Read more
One million reasons to smile
Do you like feel-good news? We know you’ll love this fabulous Huntington disease (HD) update. Thanks to our generous donors,
Read more
Novartis VIBRANT-HD Update
Update From Novartis Regarding VIBRANT-HD Clinical Trials – December 8, 2022 Dear Huntington disease (HD) community, We have received a
Read more
Promising results from SELECT-HD trial
SELECT-HD Trial Update – September 22, 2022 Dear HD Community, We are pleased to announce that Wave Life Sciences has
Read more
Announcing new Phase II clinical study, GENERATION HD 2
ANNOUNCING GENERATION HD2 – 21 September 2022 Dear HD community, We are pleased to share that Roche and Genentech have
Read more
Dear HSC Member, Notice is hereby given that the Annual General Meeting (AGM) of the Members of the Huntington Society
Read more
Update on VIBRANT-HD
Update on VIBRANT-HD – Tuesday, August 9, 2022 On Monday, August 8, 2022, Novartis announced their decision to temporarily suspend
Read more
Long-term Funding for Training Program in Huntington Disease Announced
Waterloo, ON, Sept.1, 2021: The Huntington Society of Canada (HSC) is pleased to announce the creation of a stable, long-term
Read more
Update on GENERATION HD1 and GEN-EXTEND
Today, April 27, was the first day of the annual CHDI Conference. Roche had the opportunity to present about the
Read more
- 1
- 2
- 3
- …
- 13
- Next Page »
